Business Context and Reporting Period
This Form 8-K Current Report was filed by Silo Pharma, Inc. (formerly Uppercut Brands Inc.) on September 24, 2020, with the latest event reported on October 6, 2020. The filing documents a corporate name change and a change in board composition.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and structural changes rather than financial performance.
Material Changes
- Corporate Name Change: On September 24, 2020, the Company amended its Certificate of Incorporation to change its legal name from "Uppercut Brands Inc." to "Silo Pharma, Inc."
- Board Appointment: Effective October 1, 2020, Dr. Kevin Muñoz was appointed as a director to fill a vacancy. He is deemed independent and will serve on the Audit and Compensation Committees.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No specific risks or contingencies were disclosed in this report. The appointment of Dr. Muñoz was not made pursuant to any arrangements requiring disclosure under Item 404(a) of Regulation S-K.
Key Facts for Investor Verification
- Verify the effective date of the name change to Silo Pharma, Inc. (September 24, 2020).
- Confirm Dr. Kevin Muñoz's independence status and committee assignments (Audit and Compensation).
- Note that the Company is not currently an emerging growth company based on the unchecked box in the filing.
- Review the attached press releases (Exhibits 99.1 and 99.2) for additional context on the strategic shift implied by the name change.